Pharma branding rarely means one brand. A single portfolio can span six therapeutic areas, thirty products, and forty country variants, each with its own tone, visual rules, and regulatory constraints. Most design systems collapse under that weight. Teams either ignore them and start every project from zero, or they spend weeks adapting assets that should have taken days.
This is the problem Promedia set out to solve when we built an AI-enriched semantic token design system in Figma for a pharma brand integration. Not a static component library. A living one, where every token carries context that an AI agent can read and act on.
The shift matters because the bottleneck in pharma marketing is almost never the MLR review itself. It is everything upstream: the manual adaptation, the inconsistent application of brand rules, the compliance issues discovered only after work reaches medical, legal, and regulatory reviewers. Encode brand intent into the system, and the whole cycle changes.
Start with the token layer, not the components. A pharma design system has to describe more than "primary blue" or "heading font." It has to describe why a token exists and where it is allowed to be used.
In our build, every token carries three layers of context: the visual value, the intended audience (HCP or patient), and the regulatory scope (EU, US, JP, or global). "Primary action, HCP audience, EU compliant" is now a single machine-readable object. When an AI agent generates a new asset for an EU HCP campaign, it pulls the correct token automatically. When someone tries to apply that same token to a US patient piece, the system flags it.
This is only possible because the W3C Design Tokens specification reached 1.0 stability in October 2025, and Figma shipped native import and export support the same year. Token structures are now production-ready and interoperable across the design-to-code toolchain. For pharma, that interoperability is not a nice-to-have. It is what lets brand governance survive the handoff from Figma to email platforms, e-detailing tools, and web CMSs.
The practical starting point looks like this:
MLR reviewers spend a disproportionate amount of time catching things that should never have made it into the submission: wrong logo lockup, off-brand color, missing fair balance, incorrect indication statement for the market. These are not medical judgments. They are pattern-matching tasks, and pattern-matching is what AI does well.
Our AI Brand Compliance Checker, currently a working proof of concept, compares any asset against the design system and generates a report on logo usage, fonts, colors, and brand rules before the asset reaches MLR. Today, brand compliance on emails and e-detailing is checked manually or not at all, and off-brand assets regularly reach the market. Automating that layer means MLR reviewers see clean submissions and can focus on the medical, legal, and regulatory substance.
The deeper principle, which we have written about in our MLR content, is that the review cycle is not the bottleneck. Everything that happens before submission is. Co-create with medical, legal, and regulatory at the brief stage. Build a repository of approved content and treat it as an asset. Validate globally before you localize. The AI-enriched design system operationalizes all three of those principles at the token level.
Multi-market pharma branding is where most systems break: logo lockups shift, photography rules change by audience, and the primary color used outside the US is deliberately different from the US variant. Multiply that by patient and HCP audiences, by EU, US, and JP markets, and you get combinatorial explosion.
A token-based system handles this cleanly because the variants are encoded, not memorized. A designer working on a JP HCP asset does not need to remember that the non-US primary color applies. The token knows. The AI agent applying tokens to a generated layout knows. And because mature design token systems in 2026 operate with versioning, automated testing, and deprecation policies, every change is auditable, which is exactly what regulated industries need.
With the AI-assisted approach, we see a 70 to 80 percent cost reduction per brand. For a portfolio with thirty products across forty country variants, the math is not subtle.
A static design system ages the moment it ships. A living one updates as the brand evolves, and the AI agents that read it update with it. Figma's MCP server and AI agent capabilities mean the design system can now serve as the connective tissue that guides AI tools toward brand- and accessibility-compliant outputs automatically. Designers stop re-entering brand reasoning on every project.
In practice, a new product launch in a new country compresses from weeks of adaptation to days. The AI drafts a token proposal from the source brand PDF or Figma file. Designers shape the system, validate the edge cases, and hand it back. Brand consistency holds across hundreds of touchpoints because the tokens enforce it. Compliance flags appear before MLR, not after. Productivity rises, quality rises, and regulatory risk drops.
A semantic design token is a design value, such as a color or spacing unit, paired with metadata about its meaning, purpose, and usage context. For pharma, that metadata is what makes the token useful: it can encode audience, market, therapeutic area, and compliance scope. AI agents read that context and apply the right token to the right asset without a human having to interpret brand rules each time.
Regulatory scope and audience segmentation are load-bearing, not decorative. A standard design system encodes brand. A pharma design system encodes brand plus market rules, audience-specific constraints such as HCP versus patient, and therapeutic area governance. Tokens must be auditable and versioned because every change may affect a regulated deliverable.
Yes, within a defined semantic structure. AI tools execute reliably when the rules are explicit and machine-readable. They cannot invent the meaning behind a rule, so the work sits with the human team to encode brand intent, compliance context, and market variants into the tokens. Once that structure exists, AI agents apply and check it consistently at scale.
If you manage a multi-brand, multi-market pharma portfolio, the highest-leverage move this quarter is not a rebrand or a new campaign. It is an audit of your existing brand system for token-readiness. Which rules are explicit? Which live only in reviewers' heads? What would it take to make them machine-readable?
If you want to see how the semantic token layer and the compliance checker work together, we are happy to walk your team through the build.
One short email when we publish. No spam, no sales pitch. Unsubscribe whenever.
